English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute myeloid leukemia (AML) is the most malignant type of leukemia, with new cases increasing every year worldwide and as well as with age (1), which is a class of hematopoietic stem cells, malignant clonal diseases derived from progenitor cells. Abnormal primitive cells and partial primitive immature cells (leukemia cells) in bone marrow (BM) proliferate in large quantities and inhibit normal hematopoiesis, resulting in BM failure and rapid progress (2). The prognosis of current AML patients is not optimistic, and only 40% of patients under the age of 60 survive more than 5 years. Although most patients can achieve remission after initial chemotherapy, patients who relapse after complete response rarely survive more than 5 years (3,4). Chemotherapy and hematopoietic stem cell transplantation (HSCT) have been the most important treatment for AML Original Article

Identification of six hub genes and analysis of their correlation with drug sensitivity in acute myeloid leukemia through bioinformatics